Figure 2
Figure 2. Classification tree analyses. (A) Classification tree analysis of the effect of alemtuzumab level at the time of graft infusion (±72 hours) and HLA match on acute GVHD. (B) Classification tree analysis of the effect of alemtuzumab level at the time of graft infusion (±72 hours) and underlying diagnosis (marrow failure vs non–marrow failure) on the incidence of mixed chimerism.

Classification tree analyses. (A) Classification tree analysis of the effect of alemtuzumab level at the time of graft infusion (±72 hours) and HLA match on acute GVHD. (B) Classification tree analysis of the effect of alemtuzumab level at the time of graft infusion (±72 hours) and underlying diagnosis (marrow failure vs non–marrow failure) on the incidence of mixed chimerism.

Close Modal

or Create an Account

Close Modal
Close Modal